Cisatracurium Besylate Injection USP 10mg/5mL

Neuromuscular Blocking Agent Skeletal Muscle Relaxant Anesthesia Adjunct

Cisatracurium Besylate Injection USP 10mg/5mL is a non-depolarizing neuromuscular blocking agent used to facilitate endotracheal intubation and skeletal muscle relaxation during surgical procedures or mechanical ventilation. Cisatracurium belongs to the benzylisoquinolinium class of neuromuscular blockers and provides intermediate-duration muscle relaxation without causing significant histamine release. It is widely used in anesthesia and intensive care settings due to its predictable onset, controlled duration of action, and organ-independent metabolism. The drug undergoes Hofmann elimination, a chemical degradation process independent of liver or kidney function, making it suitable for critically ill patients. Manufactured according to strict pharmaceutical quality standards, Cisatracurium Besylate Injection ensures high sterility, stability, and consistent therapeutic performance for hospital and surgical applications.

Key Information

Active Ingredient Cisatracurium Besylate 2mg/mL

Dosage Form Injection

Pack Size 2.5mL, 5mL, 10mL Vial

Storage 2°C - 8°C (Refrigerate)

Benefits

Effective muscle relaxation during surgery

Predictable onset and duration of action

Minimal histamine release

Suitable for critically ill patients

Organ-independent metabolism

Widely used in anesthesia and intensive care units

Usage Instructions

Administer intravenously by trained healthcare professionals only.

Dosage depends on the patient’s body weight, clinical condition, and anesthetic protocol.

Continuous monitoring of neuromuscular function and ventilation is required during administration.

Patients receiving this medication must be mechanically ventilated until muscle function returns.

Mechanism of Action

Cisatracurium acts by competitively blocking acetylcholine receptors at the neuromuscular junction.

This action prevents nerve impulses from stimulating muscle contraction, resulting in temporary skeletal muscle paralysis.

The drug is metabolized primarily through Hofmann elimination, producing inactive metabolites without relying heavily on liver or kidney function.

Indications

Cisatracurium Besylate Injection is indicated for:

Facilitation of endotracheal intubation

Skeletal muscle relaxation during surgical procedures

Muscle relaxation in patients undergoing mechanical ventilation in ICU

Adjunct to general anesthesia

Side Effects

Decreased blood pressure

Flushing

Slow heart rate

Precautions

Use only in facilities equipped for respiratory support

Continuous monitoring of neuromuscular function is recommended

Use cautiously in patients with neuromuscular disorders

Adjust dosage in elderly or debilitated patients

Careful administration in critically ill patients

Contraindications

Hypersensitivity to Cisatracurium or other benzylisoquinolinium neuromuscular blockers

Known allergy to any component of the formulation

Frequently Asked Questions

Find answers to common questions about Cisatracurium Besylate Injection USP 10mg/5mL

1 What is Cisatracurium Injection used for?

It is used during anesthesia to provide skeletal muscle relaxation and facilitate intubation.

2 Can this drug be used in ICU patients?

Yes, it is commonly used in intensive care units for patients requiring mechanical ventilation.

3 Does Cisatracurium depend on liver or kidney metabolism?

No, it is primarily broken down through Hofmann elimination, which is independent of liver and kidney function.

4 Who should administer this injection?

Only trained healthcare professionals in hospital settings should administer this medication.